Nomenclature
CAS number: 123122-55-4
[4(
S)-
cis]-4-[[[1-[3-[(2,3-Dihydro-1
H-inden-5-yl)oxy]-2-[(2-methoxyethoxy)methyl]-3-oxopropyl]cyclopentyl]carbonyl]amino]cyclohexanecarboxylic
acid; (α
S)-1-[(
cis-4-carboxycyclohexyl)carbamoyl]-α-[(2-methoxyethoxy)methyl]cyclopentanepropionic
acid α-5-indanyl ester; (
S)-
cis-4-[1-[2-(5-indanyloxycarbonyl)-3-(2-methoxyethoxy)propyl]-1-cyclopentanecarboxamido]-1-cyclohexanecarboxylic
acid; UK-79300.
C
29H
41NO
7; mol wt 515.64.
C 67.55%, H 8.01%, N 2.72%, O 21.72%.
Description and references
Neutral endopeptidase inhibitor. Prepn: I.
T. Barnish et al., EP 274234; eidem, US 5030654 (1988, 1991 both to Pfizer). Enzyme inhibition and pharmacology: J.
C. Danilewicz et al., Biochem.
Biophys. Res. Commun. 164, 58 (1989). Clinical
pharmacokinetics and effect on plasma ANP: J. G. Motwani et
al., Clin. Pharmacol. Ther. 54, 661 (1993). Clinical evaluation in congestive heart
failure: C. D. Kimmelstiel et al., Cardiology 87, 46 (1996).
Properties
White crystals, mp 107-109°. [α]D -5.8° (c = 1 in methanol).Derivative
Diacid.
Nomenclature
CAS number: 123122-54-3
Candoxatrilat; UK-73967.
C
20H
33NO
7; mol wt 399.48.
C 60.13%, H 8.33%, N 3.51%, O 28.04%.
Properties
White crystals from ethyl acetate, mp 108.5-109.1°. [α]D +1.4° (c = 1 in methanol).Therapeutic Category
In treatment of congestive heart failure.
Keywords
Neutral Endopeptidase Inhibitor